Abstract
This study sought to evaluate the potential of circulating long non-coding RNAs (lncRNAs) as biomarkers for acute myocardial infarction (AMI). We measured the circulating levels of 15 individual lncRNAs, known to be relevant to cardiovascular disease, using the whole blood samples collected from 103 AMI patients, 149 non-AMI subjects, and 95 healthy volunteers. We found that only two of them, Zinc finger antisense 1 (ZFAS1) and Cdr1 antisense (CDR1AS), showed significant differential expression between AMI patients and control subjects. Circulating level of ZFAS1 was significantly lower in AMI (0.74 ± 0.07) than in non-AMI subjects (1.0 ± 0.05, P < 0.0001), whereas CDR1AS showed the opposite changes with its blood level markedly higher in AMI (2.18 ± 0.24) than in non-AMI subjects (1.0 ± 0.05, P < 0.0001). When comparison was made between AMI and non-AMI, the area under ROC curve was 0.664 for ZFAS1 alone or 0.671 for CDR1AS alone, and 0.691 for ZFAS1 and CDR1AS combination. Univariate and multivariate analyses identified these two lncRNAs as independent predictors for AMI. Similar changes of circulating ZFAS1 and CDR1AS were consistently observed in an AMI mouse model. Reciprocal changes of circulating ZFAS1 and CDR1AS independently predict AMI and may be considered novel biomarkers of AMI.
Highlights
Methods149 non-Acute Myocardial Infarction Model (AMI) control subjects presented to the First Affiliated Hospital and the Second Affiliated Hospital of Harbin Medical University (Harbin, China)
Our findings suggest circulating ZFAS1 + CDR1AS as a new biomarker of Acute Myocardial Infarction Model (AMI)
Summary
149 non-AMI control subjects presented to the First Affiliated Hospital and the Second Affiliated Hospital of Harbin Medical University (Harbin, China). The healthy volunteers were recruited at the time of regular annual medical checkup and the non-AMI subjects were recruited from the patients who visited the First Affiliated Hospital and the Second Affiliated Hospital of Harbin Medical University with conditions other than AMI. All patients and control subjects included in our study belong to Han people (Han nationality). These patients were all on the first visit to our hospitals in emergency due to their chest pain and subsequent diagnosis of AMI prior to any medications to avoid their possible influence on study results.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
